Wednesday, July 8, 2026

Patent intelligence · US

US 8999996

Hydrazide containing nuclear transport modulators and uses thereof

granted A61KA61K31/4196A61K31/4439A61K31/454
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 9
Applicant portfolio 38
Patent details — US 8999996
Jurisdiction
US
Status
granted
Grant date
Apr 7, 2015
Expiration
Apr 2, 2035
Claims
2
CPC classes
A61K, A61K31/4196, A61K31/4439, A61K31/454
View on Google Patents ↗

Quick answer

US 8999996 (Hydrazide containing nuclear transport modulators and uses thereof) is held by Karyopharm Therapeutics Inc.. Status: granted. Granted Apr 7, 2015. Expires Apr 2, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
2
CPC classes
A61K, A61K31/4196, A61K31/4439, A61K31/454, A61K31/496, A61K31/497

More from Karyopharm Therapeutics Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12371420

    Polymorphs of Selinexor

    Karyopharm Therapeutics Inc. · Expires Jul 24, 2045

    granted
  2. US 12331040

    Substituted benzofuranyl and benzoxazolyl compounds and uses thereof

    Karyopharm Therapeutics Inc. · Expires Jun 12, 2045

    granted
  3. US 12318386

    Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer

    Karyopharm Therapeutics Inc. · Expires May 29, 2045

    granted
  4. US 12291508

    Hydrazide containing nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. · Expires May 1, 2045

    granted
  5. US 11945794

    Nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. · Expires Mar 28, 2044

    granted
  6. US 11807629

    Polymorphs of Selinexor

    Karyopharm Therapeutics Inc. · Expires Nov 2, 2043

    granted
  7. US 11787771

    Hydrazide containing nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. · Expires Oct 12, 2043

    granted
  8. US 11753401

    Polymorphs of Selinexor

    Karyopharm Therapeutics Inc. · Expires Sep 7, 2043

    granted

Frequently asked questions

What is US patent 8999996?

US 8999996 (Hydrazide containing nuclear transport modulators and uses thereof) is held by Karyopharm Therapeutics Inc.. Status: granted. Granted Apr 7, 2015. Expires Apr 2, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8999996?

Karyopharm Therapeutics Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.

When does US 8999996 expire?

Our index shows an expiration date of Apr 2, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.